Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Johnson & Johnson / Janssen: Clinical Trials & FDA Approval Profile

Johnson & Johnson / Janssen (New Brunswick, NJ) sponsors 300 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 122 active protocols (49 recruiting now), 123 completed protocols, and 131 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)18.3%
Median Closed Enrollment vs National (145 pts)192 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Johnson & Johnson / Janssen
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)300
Active Pipeline (Recruiting Now)122 (49)
Completed vs Stopped Early123 / 55 (18.3%)
Median Closed Actual Enrollment192 participants
Physical Hospital Site Disclosure99.4% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals131 (21 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Johnson & Johnson / Janssen
Hospital Research SiteLocationShared Protocols
Hosp. Univ. 12 de OctubreMadrid85
National Taiwan University HospitalTaipei75
Hosp. Univ. Vall D HebronBarcelona74

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Johnson & Johnson / Janssen
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06500884A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsPhase IIRECRUITING
NCT04951622A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisPhase IIIRECRUITING
NCT05179876A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionPhase IIIRECRUITING
NCT07258511A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or RefractPhase IIIRECRUITING
NCT07586202A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCPhase IIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Johnson & Johnson / Janssen Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI